Share on twitter
SHARE
Share on linkedin
SHARE

Dr Mark Bonyhadi

Share on twitter
SHARE
Share on linkedin
SHARE

Integra Therapeutics appoints Mark Bonyhadi as new independent director

Integra Therapeutics appoints Mark Bonyhadi as new independent director

Integra Therapeutics announced today that Dr Mark Bonyhadi has been appointed to its Board of Directors as an independent director.

Dr Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to the clinic and for subsequent business development.

He was vice president for Research at Juno Therapeutics Inc (acquired by Celgene Corporation), director of Global Business Development for Cell Therapy at Invitrogen (which merged to become Life Technologies and was subsequently acquired by Thermo-Fisher) and vice president for Research at Xycte Therapies. Dr Bonyhadi was formerly the chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (2015-2016). He is also the inventor on 11 patents and an author on 40 publications. He currently is a member of the scientific advisory board for Akron Biotech and is a non-executive board member for TC BioPharm.

“We are thrilled to welcome Dr Mark Bonyhadi to Integra’s Board of Directors as an independent director. His track record in research and development in advanced cell therapies will be of great value in helping our company advance its gene writing technology to the clinical stage,” says Dr Avencia Sánchez-Mejías, co-founder and CEO of Integra Therapeutics.

“I’m delighted to be joining Integra Therapeutic’s Board of Directors at such an exciting time for this pioneering company, with its FiCAT gene writing platform moving through clinical development. I look forward to contributing to its future success,” said Dr Mark Bonyhadi, the new independent director of Integra Therapeutics.

The FiCAT technology platform covers today’s main needs for efficient and safe gene therapies (gene size, precision and stability). It has the potential to tackle prevention and treatment of a wide range of genetic and oncological diseases. FiCAT has shown great promise in early-stage preclinical studies.

Integra Therapeutics recently completed its seed round with a total of €6 million from international investors AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures.